Stockreport

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

Pluri Inc.  (PLUR) 
PDF HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its propri [Read more]